EGFR;ERBB;ERBB1;HER1

Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)

Homo sapiens (Human)

134277

1210

Pending Verification

Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)

Lung cancer (LNCR) [MIM:211980]: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis. {ECO:0000269|PubMed:15118125, ECO:0000269|PubMed:16533793, ECO:0000269|PubMed:16672372}. Note=The gene represented in this entry is involved in disease pathogenesis.; Inflammatory skin and bowel disease, neonatal, 2 (NISBD2) [MIM:616069]: A disorder characterized by inflammatory features with neonatal onset, involving the skin, hair, and gut. The skin lesions involve perioral and perianal erythema, psoriasiform erythroderma, with flares of erythema, scaling, and widespread pustules. Gastrointestinal symptoms include malabsorptive diarrhea that is exacerbated by intercurrent gastrointestinal infections. The hair is short or broken, and the eyelashes and eyebrows are wiry and disorganized. {ECO:0000269|PubMed:24691054}. Note=The disease is caused by mutations affecting the gene represented in this entry.

MUTAGEN 275 275 Y->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309. {ECO:0000269|PubMed:12297050}.; MUTAGEN 287 287 F->A: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-309. {ECO:0000269|PubMed:12297050}.; MUTAGEN 309 309 R->S: Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-275. Strongly reduced autophosphorylation and activation of downstream kinases; when associated with A-287. {ECO:0000269|PubMed:12297050}.; MUTAGEN 429 429 R->E: Abolishes autophosphorylation and activation of downstream kinases. {ECO:0000269|PubMed:12297050}.; MUTAGEN 587 590 DGPH->AGPA: Decreases intramolecular interactions and facilitates EGF binding. {ECO:0000269|PubMed:12620237}.; MUTAGEN 609 609 K->A: Decreases intramolecular interactions and facilitates EGF binding. {ECO:0000269|PubMed:12620237}.; MUTAGEN 688 688 L->A: Strongly reduced phosphorylation. {ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760}.; MUTAGEN 689 689 V->A: Reduced autophosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 689 689 V->M: Constitutively activated kinase. {ECO:0000269|PubMed:19560417}.; MUTAGEN 690 690 E->A: Reduced phosphorylation. {ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760}.; MUTAGEN 692 692 L->A,P: Strongly reduced phosphorylation. {ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:19563760}.; MUTAGEN 693 693 T->A: Increased phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 693 693 T->D: Strongly reduced phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 694 694 P->A: Strongly reduced phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 699 699 P->A: Reduced phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 700 700 N->A: Abolishes phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 704 704 L->A: Abolishes phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 705 705 R->A: Abolishes phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 706 706 I->A: Abolishes phosphorylation. {ECO:0000269|PubMed:19560417}.; MUTAGEN 745 745 K->A,M: Abolishes kinase activity. {ECO:0000269|PubMed:19560417}.; MUTAGEN 974 974 D->A: Strongly reduced phosphorylation.; MUTAGEN 977 977 R->A: Reduced phosphorylation. {ECO:0000269|PubMed:19563760}.; MUTAGEN 1005 1006 ED->RK: Constitutively activated kinase. {ECO:0000269|PubMed:19563760}.; MUTAGEN 1016 1016 Y->F: 50% decrease in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1197. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1092. {ECO:0000269|PubMed:10805725}.; MUTAGEN 1048 1210 Missing: Abolishes palmitoylation. {ECO:0000269|PubMed:27153536}.; MUTAGEN 1049 1049 C->A: Decreased palmitoylation. {ECO:0000269|PubMed:27153536}.; MUTAGEN 1067 1067 Q->G: No effect on interaction with CBLC. {ECO:0000269|PubMed:22888118}.; MUTAGEN 1068 1068 R->G: Strongly decreases interaction with CBLC. {ECO:0000269|PubMed:22888118}.; MUTAGEN 1069 1069 Y->F: Abolishes interaction with CBLC. {ECO:0000269|PubMed:22888118}.; MUTAGEN 1092 1092 Y->F: No change in interaction with PIK3C2B. Abolishes interaction with PIK3C2B; when associated with F-1197 and F-1016. {ECO:0000269|PubMed:10805725}.; MUTAGEN 1110 1110 Y->F: No change in interaction with PIK3C2B. {ECO:0000269|PubMed:10805725}.; MUTAGEN 1146 1146 C->A: Decreased palmitoylation. {ECO:0000269|PubMed:27153536}.; MUTAGEN 1172 1172 Y->F: No change in interaction with PIK3C2B. {ECO:0000269|PubMed:10805725}.; MUTAGEN 1197 1197 Y->F: No change in interaction with PIK3C2B. 65% decrease in interaction with PIK3C2B; when associated with F-1016. Abolishes interaction with PIK3C2B; when associated with F-1092 and F-1016. {ECO:0000269|PubMed:10805725}.

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Plays a role in enhancing learning and memory performance (By similarity). {ECO:0000250|UniProtKB:Q01279, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11116146, ECO:0000269|PubMed:11483589, ECO:0000269|PubMed:11602604, ECO:0000269|PubMed:12297049, ECO:0000269|PubMed:12297050, ECO:0000269|PubMed:12620237, ECO:0000269|PubMed:12873986, ECO:0000269|PubMed:15374980, ECO:0000269|PubMed:15590694, ECO:0000269|PubMed:15611079, ECO:0000269|PubMed:17115032, ECO:0000269|PubMed:19560417, ECO:0000269|PubMed:20837704, ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:27153536, ECO:0000269|PubMed:2790960, ECO:0000269|PubMed:7679104, ECO:0000269|PubMed:8144591, ECO:0000269|PubMed:9419975}.; Isoform 2 may act as an antagonist of EGF action.; (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins. {ECO:0000269|PubMed:21516087}.

Active site (1); Alternative sequence (6); Beta strand (74); Binding site (2); Chain (1); Cross-link (6); Disulfide bond (25); Domain (1); Glycosylation (13); Helix (39); Lipidation (2); Modified residue (23); Mutagenesis (34); Natural variant (40); Nucleotide binding (2); Region (1); Repeat (2); Sequence conflict (1); Signal peptide (1); Site (1); Topological domain (2); Transmembrane (1); Turn (14); Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers. {ECO:0000269|PubMed:17671655}.

Epidermal growth factor receptor (EC 2.7.10.1) (Proto-oncogene c-ErbB-1) (Receptor tyrosine-protein kinase erbB-1)

Recombinant

HEK293

Lyophilized

7.4-7.5

Sterile-filtered colorless solution

1mg/ml

Standard

PBS

SDS-PAGE

> 98%

RP-HPLC

-20°C

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.